Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
In brief
Merck’s Keytruda plus Padcev combo is poised for EU approval, broadening treatment options for bladder‑cancer patients and boosting Merck’s oncology portfolio.